Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS
Status:
Terminated
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine if monthly pulse doses of a three-day
course ACTH (H.P. Acthar®) is more effective at recovering myelin at 12 months, as measured
by myelin water fraction (MWF), in new multiple sclerosis lesions as compared to one course
of treatment.
The main secondary objective is to utilize every three month MWF measurements to determine
the peak time of remyelination in new multiple sclerosis lesions when followed over the
course of 12 months.